National study finds renal stenting does not improve outcomes for renal artery stenosis patients

(Press-News.org) Contact information: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
National study finds renal stenting does not improve outcomes for renal artery stenosis patients Rhode Island Hospital researchers play lead roles in study; will present findings at the annual meeting of the American Heart Association PROVIDENCE, R.I. – According to the findings from a national research trial, people who suffer from a narrowing of the arteries that lead to the kidneys, or renal artery stenosis, do not experience better outcomes when renal stenting is used. Instead, a comprehensive regimen of drug and medical therapies works just as well. The national study, which was led by Rhode Island Hospital researchers Lance Dworkin, M.D., and Timothy Murphy, M.D., in collaboration with multiple investigators worldwide, is published in the New England Journal of Medicine (NEJM). They will also present the results at the annual meeting of the American Heart Association on November 18.

"The use of stenting to treat patients with renal artery stenosis is a treatment that clinicians have disagreed on for some time," said Dworkin, director of the Division of Hypertension & Kidney Disease at Rhode Island Hospital and a physician with University Medicine Foundation. He is the senior leader and study chair for the trial. "Our findings clearly show that renal artery stenting does not confer any benefit for the prevention of clinical events when added to a comprehensive, multi-factorial medical therapy."

The CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) study, which was the first randomized, controlled study to look at this issue, involved 947 participants at more than 100 sites in the U.S., Canada, South American, Europe, Australia and New Zealand. The participants all had atherosclerotic renal-artery stenosis and either systolic hypertension on two or more drugs or chronic kidney disease. They were randomly assigned to medical therapy plus renal-artery stenting or medical therapy alone.

Participants were then followed for up to seven years to monitor for significant clinical events, such as cardiovascular or renal death, myocardial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficiency or renal replacement therapy.

"Renal-artery stenosis is a significant public health issue, so it was important that we go beyond following blood pressure and kidney function," explained Murphy, an interventional radiologist and the medical director of the Vascular Disease Research Center at Rhode Island Hospital. He was a co-principal investigator for the study. "To really understand what benefits, if any, stenting provided, we needed to look at significant clinical events."

What researchers found was that renal stenting did not make a difference in outcomes for patients.

According to Dworkin, these results are significant as they will lead to a reduction in the number of renal stents that are inserted in patients who experience renal-artery stenosis. "Stents do a good job in opening the arteries, but less invasive medical therapies, which have only gotten better over time, means that patients can often avoid more invasive stenting procedures," he said. ### This study was funded by the National Heart, Lung and Blood Institute. Dworkin and Murphy have principal affiliations with Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island. Dworkin and Murphy also have academic appointments at The Warren Alpert Medical School of Brown University. Other researchers involved in the study are Christopher J. Cooper, M.D., University of Toledo; Donald E. Cutlip, M.D., of Harvard Clinical Research Institute and Beth Israel Deaconess Medical Center; Kenneth Jamerson, M.D., University of Michigan; William Henrich, University of Texas Health Science Center; Diane M. Reid, National Heart, Lung and Blood Institute; David J. Cohen, M.D., M.Sc., Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine; Alan H. Matsumoto, M.D., University of Virginia; Michael Steffes, M.D., University of Minnesota; Michael R. Jaff, D.O., Massachusetts General Hospital; Martin R. Prince, M.D., Ph.D., Weill Cornell Medical Center; Eldrin F. Lewis, M.D., Brigham and Women's Hospital; Katherine R. Tuttle, M.D., Providence Sacred Heart Medical Center & University of Washington School of Medicine; Joseph I. Shapiro, M.D., M.P.H., Marshall University; John H. Rundback, M.D., Holy Name Medical Center; Joseph M. Massaro, Ph.D., Harvard Clinical Research Institute and Boston University School of Public Health; and Ralph B. D'Agostino, Sr., Ph.D., Harvard Clinical Research Institute and Boston University School of Public Health. About Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $55 million in external research funding. It is also home to Hasbro Children's Hospital, the state's only facility dedicated to pediatric care. For more information on Rhode Island Hospital, visit http://www.rhodeislandhospital.org, follow us on Twitter @RIHospital or like us on Facebook http://www.facebook.com/rhodeislandhospitalpage.